Based on the STAAR Surgical Company stock forecast from 4 analysts, the average analyst target price for STAAR Surgical Company is USD 45.00 over the next 12 months. STAAR Surgical Company’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of STAAR Surgical Company is Neutral, which is based on 5 positive signals and 5 negative signals. At the last closing, STAAR Surgical Company’s stock price was USD 26.66. STAAR Surgical Company’s stock price has changed by -9.90% over the past week, -17.00% over the past month and -26.05% over the last year.
No recent analyst target price found for STAAR Surgical Company
No recent average analyst rating found for STAAR Surgical Company
Company Overview STAAR Surgical Company
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through own representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California. Read Less
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to t...Read More
Frequently Asked Questions About STAAR Surgical Company (STAA) Stock
Based on ratings from 4 analysts STAAR Surgical Company's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Neutral. The stock has 8 buy, 2 sell and hold ratings.
Unfortunately we do not have enough data on STAA's stock to indicate if its a good dividend stock.
Based on targets from 4 analysts, the average taret price for STAA is USD 45.00 over the next 12 months. The maximum analyst target price is USD 53 while the minimum anlayst target price is USD 27.
STAA stock's Price/Earning ratio is 92.16.
Our analysis grades STAA stock's Price / Earning ratio at F. This means that STAA stock's Price/Earning ratio is above 78% of the stocks in the Medical Instruments & Supplies sector in the NSD exchange.
Based on this STAA may be a overvalued for its sector.
The last closing price of STAA's stock was USD 26.66.
The most recent market capitalization for STAA is USD 1.49B.
Based on targets from 4 analysts, the average taret price for STAA is projected at USD 45.00 over the next 12 months.
This means that STAA's stock price may go up by +68.79% over the next 12 months.
We can't find any ETFs which contains STAAR Surgical Company's stock.
As per our most recent records STAAR Surgical Company has 1,056 Employees.
STAAR Surgical Company's registered address is 25651 Atlantic Ocean Drive, Lake Forest, CA, United States, 92630.
You can get more information about it from STAAR Surgical Company's website at https://www.staar.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About STAAR Surgical Company (STAA) Stock
Based on ratings from 4 analysts STAAR Surgical Company's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Neutral. The stock has 8 buy, 2 sell and hold ratings.
Unfortunately we do not have enough data on STAA's stock to indicate if its a good dividend stock.
Based on targets from 4 analysts, the average taret price for STAA is USD 45.00 over the next 12 months. The maximum analyst target price is USD 53 while the minimum anlayst target price is USD 27.
STAA stock's Price/Earning ratio is 92.16.
Our analysis grades STAA stock's Price / Earning ratio at F. This means that STAA stock's Price/Earning ratio is above 78% of the stocks in the Medical Instruments & Supplies sector in the NSD exchange.
Based on this STAA may be a overvalued for its sector.
The last closing price of STAA's stock was USD 26.66.
The most recent market capitalization for STAA is USD 1.49B.
Based on targets from 4 analysts, the average taret price for STAA is projected at USD 45.00 over the next 12 months.
This means that STAA's stock price may go up by +68.79% over the next 12 months.
We can't find any ETFs which contains STAAR Surgical Company's stock.
As per our most recent records STAAR Surgical Company has 1,056 Employees.
STAAR Surgical Company's registered address is 25651 Atlantic Ocean Drive, Lake Forest, CA, United States, 92630.
You can get more information about it from STAAR Surgical Company's website at https://www.staar.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for STAA !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
